Spectrin beta chain, non-erythrocytic 4 (SPTBN4) (SPTBN4)

Spectrin beta chain, non-erythrocytic 4 (SPTBN4) mRNA encodes a critical scaffolding protein, beta-IV spectrin, which is essential for the organization of the neuronal cytoskeleton and the clustering of voltage-gated ion channels at the nodes of Ranvier and axon initial segments (AIS) [UniProt: Q9H254]. This mRNA is primarily expressed in the central and peripheral nervous systems, where its protein product anchors sodium and potassium channels to the actin-spectrin cytoskeleton, ensuring efficient action potential propagation [PubMed: 30104744]. Mutations in the SPTBN4 gene are linked to a severe autosomal recessive neurodevelopmental disorder (NEDHBA) characterized by hypotonia, motor neuropathy, and intellectual disability [OMIM: 606214]. As a therapeutic target, SPTBN4 mRNA is being investigated for modulation via RNA-based technologies, such as antisense oligonucleotides (ASOs) or siRNA, to address conditions resulting from protein dysfunction or overexpression [PubMed: 29133302]. Additionally, altered expression of SPTBN4 has been implicated in the progression of certain cancers, suggesting its potential utility as a diagnostic biomarker or a target for gene silencing therapies [PubMed: 33458158]. Therapeutic strategies targeting this mRNA must overcome the challenge of crossing the blood-brain barrier to reach the affected neuronal populations. Precision in targeting is also required to avoid disrupting the essential structural roles of other spectrin isoforms in non-target tissues.

Other names

Beta-IV spectrinSPTB4Spectrin beta 4NEDHBAQVSPTBN4 mRNA

Antisense-mediated mRNA degradation, RNA interference (RNAi), or splice-switching to modulate protein expression.